Metabolism-resistant bradykinin antagonists: development and applications.

Abstract

Bradykinin plays many roles in normal and pathological physiology, but rapid enzymatic degradation made elucidation of its functions extremely difficult. Development of effective degradation-resistant antagonists made it possible to delineate these roles and to open the way for development of new drugs to control pathology due to excess production of bradykinin. Presently available peptide bradykinin antagonists are extremely potent, are completely resistant to enzymatic degradation, and are orally available. Non-peptide bradykinin antagonists have also been discovered. Development of bradykinin antagonists as drugs for cancer, inflammation and trauma is anticipated.

• Authors: J M Stewart, L Gera, E J York, D C Chan, E J Whalley, P A Bunn Jr, R J Vavrek
• Journal: Biological chemistry (Biol Chem) Vol. 382 Issue 1 Pg. 37-41 (Jan 2001) ISSN: 1431-6730 [Print] Germany
• PMID: 11258669 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Kinins
• Peptides
• Receptors, Cell Surface

Topics

• Animals
• Biological Assay
• Humans
• Kinins (metabolism)
• Peptides (pharmacology)
• Receptors, Cell Surface (agonists, antagonists & inhibitors, classification)
• Species Specificity